Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Revance Therapeutics, Inc. (RVNC)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21
   10-Q10-Q10-Q10-Q10-Q10-K10-Q10-Q
Revenue:          
Total revenue    108.699.389.877.863.047.1
            Total revenue growth    72.4%111.0%214.2%407.7%1371.2%9467.3%
Operating expenses:          
Cost of product revenue /service revenue (exclusive of amortization)          
Selling, general and administrative    205.1192.1194.9198.8205.2200.6
Research and development    111.2115.2119.7116.3116.6115.6
Depreciation and amortization     7.73.8   
    Total operating expenses    543.2520.0606.6681.5688.9670.6
    Loss from operations    -259.2-254.4-266.9-274.7-291.0-295.4
            Operating margin    -238.6%-256.1%-297.3%-353.1%-462.1%-627.7%
Interest income    1.90.90.30.31.72.0
Interest expense    -14.3-8.9-6.6-6.3-9.1-11.9
Other expense, net    -0.6-0.9-0.9-0.8-0.8-0.8
    Net loss    -273.6-263.3-274.0-281.3-296.5-303.4
    Comprehensive loss    -274.0-263.6-274.1-281.3-296.5-303.5
    Basic net loss    -273.6-263.3-274.0-281.3-296.5-303.4
    Diluted net loss    -273.6-263.3-274.0-281.3-296.5-303.4
   
Basic net loss (in dollars per share)    ($3.92)($3.85)($4.04)($4.18)($4.49)($4.73)
Diluted net loss (in dollars per share)    ($3.92)($3.85)($4.04)($4.18)($4.49)($4.73)
   
Basic weighted-average number of shares used in computing net loss per share    69.568.467.867.365.063.2
Diluted weighted-average number of shares used in computing net loss per share    69.568.467.867.365.063.2

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy